In This Issue
Welcome to the fall issue of MedConnect, a quarterly newsletter with valuable insights and intelligence on pharmacy benefit management and healthcare. Throughout the year we offer news and thought leader analyses to help you better understand trends in healthcare so you can work smarter and stay ahead of the competition.
In this edition we are introducing a new feature: Top Drugs. This section will offer a look at statistics on top drugs by claim cost and volume, in a graphic, easy-to-digest format. You'll also find a link to a downloadable version of the information that makes it easy to share. This month's edition features the top rheumatoid arthritis (RA) drugs.
Additional content in this issue includes:
- Drug Info ─ PCSK9 Inhibitors: A Glimpse at the Future Treatment of High Cholesterol
- Specialty Rx ─ High Cholesterol Treatments: Does New Equal Improved?
- 340B ─ HRSA Releases Much-anticipated 340B MegaGuidance
- Self-Funded ─ High Deductible Health Plans – Market Changes and Growth since the Passage of the ACA
- MCO Commercial ─ Reduce Costs with MedImpact’s Pharmacy Flu Program
- Upcoming events ─ Registration for the 2016 MedImpact Annual Conference is now open!
This newsletter is for you, so we encourage you to send us feedback. Submit your comments and article suggestions here. We look forward to hearing from you!